局部苯妥英与安慰剂治疗乳腺癌患者急性放射性皮炎:一项双盲随机对照试验

IF 0.4 Q4 ONCOLOGY
E. Zabihi, Mobina Zamani, A. Vallard, N. Magné, D. Moslemi
{"title":"局部苯妥英与安慰剂治疗乳腺癌患者急性放射性皮炎:一项双盲随机对照试验","authors":"E. Zabihi, Mobina Zamani, A. Vallard, N. Magné, D. Moslemi","doi":"10.5812/ijcm-125163","DOIUrl":null,"url":null,"abstract":"Background: Acute radiodermatitis (ARD) is a common side effect of breast cancer radiotherapy. It includes erythema, burning sensation, swelling, epilation, desquamation, ulceration, or necrosis. So far, there has been no consensus about the best practice in preventing /treating ARD. Objectives: This is the first study to assess the efficacy of topical phenytoin in the prevention and treatment of ARD. Methods: This prospective randomized double-blind trial was a placebo-controlled study. A total of 70 patients with breast cancer were included. They were referred for breast radiotherapy after radical mastectomy. Patients were randomly assigned to either the topical phenytoin or placebo group. Both ointments were applied twice and daily on affected areas of the chest. Acute radiodermatitis was evaluated every week, for 5 weeks, during radiotherapy. A blinded-to-treatment physician used the “(radiation therapy oncology group) RTOG dermatitis scoring” to do so. Results: During the first 3 weeks, ARD was neither severe (RTOG < 2) nor statistically different between the two treatment groups (P > 0.05). However, after the 3rd week, the ARD score was lower in phenytoin group than in the placebo group (P < 0.05). Conclusions: Phenytoin topical ointment could postpone the occurrence and/or decrease the severity of ARD in patients with breast cancer.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Topical Phenytoin Versus Placebo in the Management of Acute Radiation-Induced Dermatitis in Patients with Breast Cancer: A Double-Blind Randomized Controlled Trial\",\"authors\":\"E. Zabihi, Mobina Zamani, A. Vallard, N. Magné, D. Moslemi\",\"doi\":\"10.5812/ijcm-125163\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Acute radiodermatitis (ARD) is a common side effect of breast cancer radiotherapy. It includes erythema, burning sensation, swelling, epilation, desquamation, ulceration, or necrosis. So far, there has been no consensus about the best practice in preventing /treating ARD. Objectives: This is the first study to assess the efficacy of topical phenytoin in the prevention and treatment of ARD. Methods: This prospective randomized double-blind trial was a placebo-controlled study. A total of 70 patients with breast cancer were included. They were referred for breast radiotherapy after radical mastectomy. Patients were randomly assigned to either the topical phenytoin or placebo group. Both ointments were applied twice and daily on affected areas of the chest. Acute radiodermatitis was evaluated every week, for 5 weeks, during radiotherapy. A blinded-to-treatment physician used the “(radiation therapy oncology group) RTOG dermatitis scoring” to do so. Results: During the first 3 weeks, ARD was neither severe (RTOG < 2) nor statistically different between the two treatment groups (P > 0.05). However, after the 3rd week, the ARD score was lower in phenytoin group than in the placebo group (P < 0.05). Conclusions: Phenytoin topical ointment could postpone the occurrence and/or decrease the severity of ARD in patients with breast cancer.\",\"PeriodicalId\":44764,\"journal\":{\"name\":\"International Journal of Cancer Management\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/ijcm-125163\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-125163","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:急性放射性皮炎(ARD)是乳腺癌放疗的常见副作用。它包括红斑、烧灼感、肿胀、脱毛、脱屑、溃疡或坏死。到目前为止,对于预防/治疗ARD的最佳做法还没有达成共识。目的:这是第一个评估局部苯妥英预防和治疗ARD疗效的研究。方法:前瞻性、随机、双盲、安慰剂对照研究。共纳入了70名乳腺癌患者。她们在根治性乳房切除术后接受乳房放射治疗。患者被随机分配到局部苯妥英或安慰剂组。这两种药膏每天两次涂抹在胸部的患处。急性放射性皮炎在放射治疗期间每周评估一次,持续5周。一名不接受治疗的医生使用“(放射治疗肿瘤组)RTOG皮炎评分”来做到这一点。结果:治疗前3周,两组患者ARD均不严重(RTOG < 2),差异无统计学意义(P > 0.05)。然而,第3周后,苯妥英组的ARD评分低于安慰剂组(P < 0.05)。结论:苯妥英外用软膏可延缓乳腺癌患者ARD的发生和/或降低其严重程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Topical Phenytoin Versus Placebo in the Management of Acute Radiation-Induced Dermatitis in Patients with Breast Cancer: A Double-Blind Randomized Controlled Trial
Background: Acute radiodermatitis (ARD) is a common side effect of breast cancer radiotherapy. It includes erythema, burning sensation, swelling, epilation, desquamation, ulceration, or necrosis. So far, there has been no consensus about the best practice in preventing /treating ARD. Objectives: This is the first study to assess the efficacy of topical phenytoin in the prevention and treatment of ARD. Methods: This prospective randomized double-blind trial was a placebo-controlled study. A total of 70 patients with breast cancer were included. They were referred for breast radiotherapy after radical mastectomy. Patients were randomly assigned to either the topical phenytoin or placebo group. Both ointments were applied twice and daily on affected areas of the chest. Acute radiodermatitis was evaluated every week, for 5 weeks, during radiotherapy. A blinded-to-treatment physician used the “(radiation therapy oncology group) RTOG dermatitis scoring” to do so. Results: During the first 3 weeks, ARD was neither severe (RTOG < 2) nor statistically different between the two treatment groups (P > 0.05). However, after the 3rd week, the ARD score was lower in phenytoin group than in the placebo group (P < 0.05). Conclusions: Phenytoin topical ointment could postpone the occurrence and/or decrease the severity of ARD in patients with breast cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
67
期刊介绍: International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信